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Background: Drug development for rare diseases is challenging, especially when these orphan drugs (OD) are
intended for children. In 2007 the EU Paediatric Drug Regulation was enacted to improve the development of high
quality and ethically researched medicines for children through the establishment of Paediatric Investigation Plans
(PIPs). The effect of the EU Paediatric Drug Regulation on the marketing authorisation (MA) of drugs for children
with rare diseases was studied.
Methods: Data on all designated orphan drugs, their indication, MA, PIPs and indication group (adult or child) were
obtained from the European Medicines Agency (EMA). The outcome and duration of the process from orphan drug
designation (ODD) to MA, was compared, per indication, by age group. The effect of the Paediatric Drug
Regulation, implemented in 2007, on the application process was assessed with survival analysis.
Results: Eighty-one orphan drugs obtained MA since 2000 and half are authorised for (a subgroup of) children;
another 34 are currently undergoing further investigations in children through agreed PIPs. The Paediatric Drug
Regulation did not significantly increase the number of ODDs with potential paediatric indications (58% before
vs 64% after 2007 of ODDs, p = 0.1) and did not lead to more MAs for ODs with paediatric indications (60% vs 43%,
p = 0.22). ODs authorised after 2007 had a longer time to MA than those authorised before 2007 (Hazard ratio (95%
CI) 2.80 (1.84-4.28), p < 0.001); potential paediatric use did not influence the time to MA (Hazard ratio (95% CI) 1.14
(0.77-1.70), p = 0.52).
Conclusions: The EU Paediatric Drug Regulation had a minor impact on development and availability of ODs for
children, was associated with a longer time to MA, but ensured the further paediatric development of drugs still
off-label to children. The impact of the Paediatric Drug Regulation on research quantity and quality in children
through PIPs is not yet clear.
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Rare diseases are defined as life-threatening or chronic-
ally debilitating conditions with such a low prevalence
that special combined efforts are needed to ensure ad-
equate medical care. As a guide, a prevalence of less
than 5 per 10,000 citizens in the European Union (EU)
is considered low [1]. A low prevalence still equals to ap-
proximately 250,000 patients in the Community for dis-
eases near the cut-off point. Much rarer diseases only
affect a few dozen patients in the whole EU. There are
between 5000 and 8000 rare diseases identified so far, af-
fecting an estimated 30 million EU citizens [2]. Over
80% of rare diseases have a genetic background, with the
great majority being single-gene defects, although multi-
factorial and chromosomal defects exist. Other non-genetic
rare diseases are due to degenerative and proliferative
causes, infectious diseases, treatment-related toxicities, ali-
mentary deficiencies, rare poisonings and injuries [2,3].
Rare diseases can occur at any age but approximately half
of these have their onset at birth or during childhood [4].
Drugs for rare diseases are classified as orphan drugs
(ODs). Developing ODs is very challenging. This is
mainly due to the various factors that limit clinical stud-
ies such as the small number of patients, the heteroge-
neous and scattered populations, ethical issues (i.e. the
use of placebo), lack of validated biomarkers and end-
points, poor diagnostics and limited clinical expertise
[5], but also by the lack of return of investment in the
small target population [6]. To stimulate research, devel-
opment and placing on the market of ODs, in 2000, in-
centives were put in place for drug developers, such as a
ten-year marketing exclusivity, access to centralised au-
thorisation procedures and fee reductions for regulatory
activities (such as protocol assistance, MA applications
and inspections) by the European Medicines Agency
(EMA) [6]. Another mechanism that may boost the dis-
covery and development of ODs is “repurposing”. This
refers to the exploitation of known drugs for new indica-
tions [7]. Repurposing receives attention in both the
United States and Europe, although differences exist be-
tween both continents with respect to policies for repur-
posing of medicinal products [8]. Several initiatives have
been created to identify possible targets for drug reposi-
tioning [7]. One of them is the US Food and Drug Ad-
ministration (FDA) Rare Diseases Repurposing Database
to encourage repurposing for rare diseases [9]. There are
many examples of ODs that were successfully developed
from repurposed drugs [10,11].
The development of drugs for children with rare dis-
eases poses even more challenges than it does for adults.
The biology of the growing child, its changing physi-
ology and psychology are much different from adults
and requires research that is dedicated to children [12].
Such research is confronted by technical difficulties andlegal and ethical constraints. As a consequence, there is
little or no investment in research and development of
drugs for the paediatric population. More than half of
medicines used for children were never or incompletely
studied in this population; their use in children is either
unlicensed or off label, i.e. out of the scope of the drug’s
authorised label for age, route of administration, dose
frequency, formulation or indication [13]. Use of
unlicensed drugs or off-label use is especially common
for children with rare diseases and is potentially ineffica-
cious and hazardous [14].
The European Regulation (EC) No 1901/ 2006, herein-
after referred to as the ‘Paediatric Drug Regulation’ [1]
came into force on 26 January 2007 with the objective to
improve the health of European children by facilitating
the development, accessibility and safe use of new drugs
for children aged 0 to 17 years, through clinical studies.
These objectives should be achieved without subjecting
children to unnecessary clinical trials and without delay-
ing the authorisation for other age populations. This
regulation obliges applicants to submit study results to
the EMA for each new medicine, new indication, new
route of administration or new formulation, according
to an agreed Paediatric Investigation Plan (PIP). This
PIP describes the planned paediatric studies and their
timelines. It should ideally cover all age groups from
birth to adolescence. Paediatric studies may be (partially)
‘waived’ if studies are not feasible, appropriate or safe for
(a subset of ) the paediatric population or ‘deferred’ if it
is appropriate to conduct studies in adults prior to initi-
ating studies in children or if studies in children will last
longer than studies in adults. The PIP should also de-
scribe the need for the development of age-appropriate
formulations and/or additional non-clinical information
(such as developmental toxicity studies in juvenile ani-
mal). When the PIP is completed and all requirements
are met, applicants are rewarded with a six month ex-
tension of patent protection. Off-patent products devel-
oped exclusively for use in children are granted eight
year data- and ten year market exclusivity for the paedi-
atric indication (the Paediatric Use Marketing Authorisa-
tion (PUMA)). ODs are rewarded with two additional
years of market exclusivity. The Paediatric Drug Regula-
tion was introduced in stages (see Table 1) distinguishing
new medicinal products from already authorised medi-
cinal products.
The implementation of the Paediatric Drug Regulation
has paid off for non-orphan medicinal products. Five
years after its implementation, more medicines have
become available for children and more research has
been conducted in children [15]. Over 600 PIPs have
been agreed upon and 30% of those PIPs include studies
with neonates, the most neglected group. In addition,
more paediatric clinical trials were conducted and the
Table 1 Implementation phases of the Paediatric Drug Regulation (EC) No 1901/2006
Category Application Jurisdiction Implementation
Off-patent medicine MA for a paediatric use Article 30 26 July 2007
New medicine MA that includes a paediatric indication Article 7 26 July 2008
On-patent medicine To include a paediatric indication in an existing MA* Article 8 26 January 2009
*New indications, pharmaceutical forms and/ or routes of administration which are protected by a supplementary protection certificate or by a patent which
qualifies for the granting of a supplementary protection certificate.
All three categories need to comply with the requirements of Article 7: application for MA should include the results of all studies conducted in compliance with
an agreed PIP or a decision of the EMA granting a (partial) waiver or deferral [1].
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over the last 6 years, to approximately 10% [15].
For ODs, the impact of the Paediatric Drug Regulation
has not been studied. In this manuscript, we describe
the drug application process from orphan drug designa-
tion (ODD) to marketing authorisation (MA) and ana-
lyse the effect of the Paediatric Drug Regulation on the
success rate and time course of obtaining MA.
Methods
Orphan drug designations and marketing authorisations
The EMA kindly provided us with a list of all ODDs
from 2000 until December 2012 with designation date
and number, indication and age category for which the
OD is intended (children and/or adults, i.e. potential
paediatric use or not). Designations are issued for treat-
ment indications so that drugs with more than one indi-
cation occur more than once in this list. Of all ODDs
that obtained MA, the European Public Assessment Re-
ports (EPARs) and the product information (Summary
of Product Characteristics [SmPC]) available at the EMA
website (www.ema.europa.eu) were studied. The follow-
ing information was extracted: authorisation date, approval
conditions (i.e. conditional approval or under exceptional
circumstances), indication and age category (children,
adults or both) for which the product was authorised. All
authorised ODs were cross referenced with the Community
register (available at http://ec.europa.eu/health/documents/
community-register/html/index_en.htm) of both ODs and
drugs for human use to determine whether the authorised
products still benefited from an orphan status or not.
Paediatric investigation plans
Of all authorised ODs, submitted PIPs including waivers,
deferral agreements as well as description and timelines
of the required studies (clinical, non-clinical and formu-
lations) were extracted from the EMA website. As a rule,
a PIP has to include all subsets of the paediatric popula-
tion, but waivers for the entire paediatric population (full
waivers) or for certain age groups (partial waivers) are
granted when one of the following conditions are met:
the condition only occurs in the adult population; cli-
nical studies cannot be expected to be of significant
therapeutic benefit or are not feasible; the product isconsidered unsafe or ineffective in children. Full waivers
can be granted for classes of medicinal products (‘class
waivers’) or for specific medicinal products (‘product
specific waiver’).
In case of a deferral, the initiation or completion of
paediatric studies described in the PIP is postponed until
after MA for adults [1].
Time course to marketing authorisation
The influence of the Paediatric Drug Regulation on the
time course of obtaining MA after ODD was analysed
using SPSS software version 22.0 (IBM Corp, Armonk,
NY, USA). Chi-square was used for subgroup analyses
and Cox proportional hazards models were used to
examine the impact of potential paediatric use (intended
for children yes/no) and approval after or before 2007
(the year in which the Paediatric Drug Regulation was
introduced) on time to MA for a designated orphan in-
dication. In order to analyse these effects, the database
was restructured from a list of drugs with children and
adult indications as separate variables to a table with
drug- indication- age combinations. A drug with mul-
tiple indications for both children and adults can thus
appear more than once in this table. ODD after or be-
fore 2007 was entered as separate variable. Time to
event was computed as the time elapsed between ODD
and MA for every drug-indication-age combination.
Since a correlation can be assumed between obtaining
authorisation for a paediatric indication and an adult
indication for the same medicinal compound, the ana-
lysis was also repeated for drugs irrespective of indica-
tion by age. When designated orphan products were
not authorised yet, the case was censored at the date of
analysis.
The effect of repurposing could only be analysed for
products with MA using the definition as described by
Norman (2013) [10]. This variable was not available for
drugs without MA (censored cases). Therefore this vari-
able was not analysed with survival analysis but with
General Linear Model (GLM) only. The mean time from
ODD to MA was also calculated using the GLM proce-
dure with the following covariates: after/before 2007 and
paediatric indication (yes/no).
Differences were taken as significant at P < 0.05.
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Orphan drug designations and marketing authorisations
From the implementation of the OD Regulation in 2000
until December 2012, 1088 ODDs were granted, 670
(62%) were intended for children (either exclusively
for children (n = 161) or for both children and adults
(n = 509)) and 418 (38%) were for adults only (Figure 1).
As of November 2013, 81 of all granted ODDs had ob-
tained MA. Sixty-five of these were identified as having
a potential paediatric use at the time of ODD. Forty of
these have indeed become available for children (‘on-
label’); 25 potential paediatric products were still off
label for children at the time of MA and 16 products
were for adults only.
Of the 40 on-label paediatric ODs, 16 are currently
under further development for a subset of the paediatric
population. The PIP details of these ODs are specified in
Table 2.
Of the 25 ODs that are authorised for adults but still
off label for children, fifteen products are currently
undergoing further development for use in children
(Table 3), while the remaining ten are not. Two of those
were granted a product specific waiver because the me-
dicinal product did not represent a significant thera-
peutic benefit over existing treatment for paediatric
patients while the remaining eight products did not have
a PIP (see below for further details).
For the sixteen ODs for adults, four class waivers were
granted for the following conditions: multiple myeloma
(n = 2), myelofibrosis (n = 1) and chronic lymphocyticFigure 1 Schematic overview of potential and authorised treatment p
designations (ODDs) for either adults only (upper line) or with a potential p
arrows represent those that obtained MA. The thick vertical line represents
obtained MA after 2007 (middle section: designation date before 2007, righ
represent ODs that are undergoing further research in the paediatric popu
arrows are not undergoing further research in children).leukaemia (n = 1). Five product specific waivers were
granted because the condition only occurs in the adult
population (n = 3), because the medicinal product did
not represent a significant therapeutic benefit over exist-
ing treatment for paediatric patients (n = 1) or because
the product was likely to be unsafe in the paediatric
population (n = 1). For four products, no PIP was found.
One of these was authorised after 2007 but before the
implementation of article 8 (in January 2009). Note-
worthy is the fact that the potential indication of three
products was initially considered for ‘adults only’ at time
of ODD, but these products are currently undergoing
paediatric investigations, meaning that they are consid-
ered to be of potential paediatric use after all (Table 4).
Paediatric investigation plans
For 36 authorised ODs no decision or information about
a PIP was found. For the majority of the products a PIP
was not required because approval was granted before
the Paediatric Drug Regulation came into force (n = 19)
or because application for MA was submitted before the
implementation of article 7 (n = 4) or article 8 (n = 1).
Unless the applicant files for extension or variation of
the initial MA, these medicinal products are likely to
remain off label to children. The remaining 12 prod-
ucts without a PIP were developed for (a subgroup of )
children.
For 34 authorised ODs, the PIP was required to in-
clude development and testing of an age appropriate for-
mulation or conducting non-clinical and clinical studies.opulations. The horizontal pipeline indicates the orphan drug
aediatric indication (lower line) over time (2000 – 2012) and the
the year 2007. Arrows to the right of the thick line are all ODDs that
tmost: designation date after 2007). Arrows with broken outline
lation (i.e. with an agreed PIP after having received MA, while solid
Table 2 PIP details of ODs that are authorised for use in children
Medicine name
(active substance)





Decision‡ Condition and age covered by waiver Ground for waiver Expected date of
completion §
Elaprase (idursulfase) Yes All PW Mucopolysaccharidosis II (Hunter syndrome)
(Girls birth to < 18 y)
Condition does not occur in the
specified paediatric subset
December 2015
Exjade¶ (deferasirox) Yes 2 PW Chronic iron overload requiring chelation therapy




Glivec* (imatinib) Yes 1 PW Pulmonary arterial hypertension (PAH)
(birth to <6 months)
Likely ineffective May 2013: PIP completed
Philadelphia chromosome (BCR-ABL translocation) -
positive chronic myeloid leukaemia (birth to <18 years)
No significant therapeutic
benefit
Treatment of Philadelphia chromosome (BCR-ABL
translocation) - positive acute lymphoblastic
leukaemia (birth to < 1 year).
Condition does not occur in the
specified paediatric subset
Ilaris (canakinumab) Yes 2 PW Juvenile idiopathic arthritis (birth to < 24 months) Condition does not occur in the
specified paediatric subset and
no significant therapeutic benefit
June 2015
Cryopyrin Associated Periodic Syndromes
(CAPS) including: FCAS, FCU, MWS, NOMID
and CINCA* (birth to < 28 days)
No significant therapeutic
benefit
Inovelon (rufinamide) Yes 4 PW Lennox-Gastaut syndrome (birth to < 12
months and from 4 to <18 years)
Condition does not occur in the
specified paediatric subset and




Yes 4 PW Hyperphenylalaninemia (4 to < 18 years) No significant therapeutic
benefit
January 2014
Mozobil (Plerixafor) Yes All PW Myelosuppression caused by chemotherapy to
treat malignant disorders, which requires an
autologous haematopoietic stem cell transplant




Novothirtheen (catridecacog) Yes 6 PW Prevention of bleeding during surgical interventions
in congenital factor XIII A-subunit deficiency and
treatment of bleeding in congenital factor XIII
A-subunit deficiency (birth to <18 years)
Condition does not occur in the
specified paediatric subset
December 2015
For the prevention of bleeding in congenital
factor XIII A-subunit deficiency (birth to <1 year)
No significant therapeutic
benefit
Tobi Podhaler (tobramycin) Yes 6 PW Pseudomonas aeruginosa pulmonary
infection/colonisation in patients with
cystic fibrosis (birth to < 3 months)





Yes 3 PW Systemic sclerosis and of interstitial
pulmonary (birth to < 18 years)
Condition does not occur in
the specified paediatric subset
December 2013
Pulmonary arterial hypertension (PAH)
(from 28 days to < 3 months and






















Table 2 PIP details of ODs that are authorised for use in children (Continued)
Votubia (everolimus) Yes 3 PW Angiomyolipoma
(birth to < 18 years)
Condition does not occur
in the specified paediatric subset
March 2020
Subependymal giant cell astrocytoma
and tuberous Sclerosis Complex (NA)
NA
Vpriv (velaglucerase alfa) Yes 3 PW Gaucher Disease, Type 2
(birth to < 18 years)
Likely ineffective July 2015
Gaucher Disease, types 1 and 3
(from birth to < 24 months)
No significant therapeutic
benefit
Xagrid¶ (anagrelide) Yes All PW Essential Thrombocythaemiaa
(birth to < 6 years)
Condition does not occur in
the specified paediatric subset
March 2013
Kalydeco (ivacaftor) Yes 6 FP NA NA December 2016
Orfadin¶ Yes All FP NA NA May 2013
Revatio¶ Yes 1 FP NA NA July 2014
*Intended for the paediatric population at time of ODD (yes/no).
†Minimum age (in years) on SmPC at time of MA. All: age range not specified and/ or no age contraindication.
‡PIP decision granted by EMA: PW: partial waiver, FP: Full investigation plan, for the entire paediatric population. NA: Not applicable.
§Expected date of PIP completion for the remaining population.
¶Product was authorised before 2007 however the MAH applied for or had the intention to apply for an extension of the authorised indication. Consequently, pursuant to Article 8 of Regulation (EC) No 1901/2006,
the MAH submitted a PIP.





















Table 3 PIP details of potential paediatric ODs that are off-label to children





Decision‡ Condition and age covered by waiver Ground for waiver Expected date of
completion
Signifor (pasireotide diaspartate) Yes No PSW Pituitary dependent Cushing, overproduction
of pituitary ACTH, pituitary dependant
hyperadrenocorticism and the treatment
of acromegaly and pituitary gigantism
(birth to <18 y)
No significant therapeutic benefit Not applicable
Vyndaqel (Tafamidis) Yes No PSW Neuropathic heredofamilial (birth to <18 y) No significant therapeutic benefit Not applicable
Adcetris (brentuximab vedotin) Yes No PW Hodgkin (birth to < 5 y); Anaplastic large cell
lymphoma (birth to < 2y)
Both conditions do not occur in
the specified paediatric subset
December 2018
Bronchitol (mannitol) Yes No PW Cystic Fibrosis with pulmonary disease
(birth to <6y)
No significant therapeutic benefit April 2011
Cayston (aztreonam lysine) Yes No PW Treatment of gram-negative endobronchial
infection in bronchiectasis patients
(birth to <18 y)
No significant therapeutic benefit October 2016
Treatment of Pseudomonas aeruginosa
(PA) pulmonary infection/colonisation
in patients with cystic fibrosis (CF)
(birth to <3 months)
No significant therapeutic benefit
Dacogen (decitabine) Yes No PW Acute myeloid leukaemia (birth to < 28 days) No significant therapeutic benefit July 2021
Firazyr (icatibant) Yes No PW ACE inhibitor-induced angioedema
(birth to < 18)
No significant therapeutic benefit December 2017
Hereditary angioedema (birth to < 2 years No significant therapeutic benefit
Glybera (alipogene tiparvovec) Yes No PW Hyperchylomicronaemia (birth to < 2 years) Likely unsafe December 2021




(birth to <1 y)
No significant therapeutic benefit
Nplate (romiplostim) Yes No PW Disease-related thrombocytopenia in
myelodysplastic syndrome
(birth to <18 years)
Likely unsafe December 2014
Immune thrombocytopenia
(birth to <1 y)
No significant therapeutic benefit
Plenadren (hydrocortisone) Yes No PW Adrenocortical Insufficiency
(6 years to < 18 y)
No significant therapeutic benefit October 2016
Revestive (Teduglutide) Yes No PW Short bowel syndrome
(birth to < 4 months)
No significant therapeutic benefit February 2017
Revolade (eltrombopag olamine) Yes No PW Idiopathic Thrombocytopenia Purpura
(birth to <1 y) Secondary
thrombocytopenia: NA






















Table 3 PIP details of potential paediatric ODs that are off-label to children (Continued)
Soliris (eculizumab) Yes No PW Paroxysmal Nocturnal Haemoglobinuria
(PNH) (birth to < 2 y)
Condition does not occur in the specified
paediatric subset
June 2019
STEC-HUS patients: NA AHUS: NA Conditions do not occur in the specified
paediatric subset
Sprycel§ (Dasatinib) Yes No PW Philadelphia chromosome (BCR-ABL
translocation)-positive chronic myeloid
leukaemia (0-1y) and Philadelphia
chromosome (BCR-ABL translocation)-positive
acute lymphoblastic leukaemia (0-1y)
Condition does not occur in the specified
paediatric subset
June 2018
Sutent§ Yes No PW Gastro-intestinal stromal tumour (0-6y) Condition does not occur in the specified
paediatric subset
June 2014
NexoBrid (concentrate of proteolytic enzymes
enriched in bromelain)
Yes No FP NA NA March 2019
*Intended for the paediatric population at time of ODD.
†Paediatric use specified on SmPC at time of MA (yes/no).
‡PIP decision granted by EMA: CW: Class Waiver, PSW: product specific waiver W: full waiver in all subsets of the paediatric population, PW: partial waiver, FP: Full investigation plan, for the entire paediatric population.
NA: Not applicable.
§Product was authorised before 2007, however the MAH applied or had the intention to apply for an extension of the authorised indication. Consequently, pursuant to Article 8 of Regulation (EC) No 1901/2006, the
MAH submitted a PIP. FCAS: Familial Cold Autoinflammatory Syndrome; FCU: Familial Cold Urticaria; MWS: Muckle-Wells Syndrome; NOMID: Neonatal-Onset Multisystem Inflammatory Disease; CINCA: Chronic Infantile




















Table 4 Waiver conditions of ‘adults only’ OD
Medicine name (active
substance)





Decision‡ Condition and age covered by waiver Ground for waiver Expected date of completion PIP for
remaining population
Arzerra (ofatumumab) No No CW Chronic lymphocytic leukaemia (birth to <18y) Class waiver NA
Imnovid (pomalidomide) No No CW Multiple myeloma (birth to <18y) Class waiver NA
Jakavi (ruxolitinib) No No CW Myeolofibrosis (birth to <18y) Class waiver NA
Thalidomide Celgene
(thalidomide)
No No CW Multiple myeloma (birth to <18y ) Class waiver NA
Afinitor (everolimus) No No PSW Renal cell carcinoma and pancreatic neuroendocrine
tumour (birth to <18y)
Condition occurs only in
adult populations
NA
Esbriet (pirfenidone) No No PSW Idiopathic Pulmonary Fibrosis (birth to <18y) Condition occurs only in
adult populations
NA
Nexavar§ (Sorafenib) No No PSW Differentiated thyroid cancer (birth to <18y) No significant therapeutic
benefit over existing treatments
for paediatric patients.
NA
Revlimid (lenalidomide) No No PSW Multiple myeloma and myelodysplastic syndromes (birth
to <18 y)
Likely unsafe NA
Torisel (temsirolimus) No No PSW For the treatment of mantle-cell lymphoma for all sub-




Bosulif (bosutinib) No No PW Chronic myeloid leukaemia (birth to <10 y) Condition occurs only
in adult populations
December 2016





Volibris (ambrisentan) No No PW Pulmonary arterial hypertension (0-1y) Likely unsafe December 2016
*Intended for the paediatric population at time of ODD (yes/no).
†Paediatric use specified on SmPC at time of MA.
‡PIP decision granted by EMA: CW: Class Waiver , PSW: product specific waiver; PW: partial waiver; NA: Not applicable.
§Product was authorised before 2007, however the MAH applied or had the intention to apply for an extension of the authorised indication. Consequently, pursuant to Article 8 of Regulation (EC) No 1901/2006, the
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remaining four products were required to develop and
assess treatment for the complete paediatric population.
None of the PIPs were completed at the time of applica-
tion for MA as some of the requirements in the PIP
were deferred. Partial waivers were mostly granted based
on the expectation that clinical studies would be of no
significant therapeutic benefit or fulfil no therapeutic
need of the paediatric population. PIP decisions, waiver
conditions and expected date of PIP completion are de-
scribed in Tables 2, 3 and 4.
Half of the 34 products with a PIP were required to ei-
ther develop an age-appropriate formulation or to assess
the acceptability of the existing formulation (Table 5).
The majority of these measures applied to oral formula-
tions (n = 13). An age-appropriate diluted formulation
was required for intravenous (n = 1) and subcutaneous
(n = 2) formulations.
For 15 products non-clinical studies had to be per-
formed. The required measures mostly included juvenile
animal studies to determine pharmacokinetics, tolerabil-
ity, toxicology and/ or toxicokinetics. In some cases, spe-
cific pharmacology, exploratory or dose ranging studies
were required in vitro or in other animal models.
All 34 products with a PIP required at least one clinical
study in children (median = 3, range 1–9 studies). A quar-
ter (n = 25) of the studies were randomised double-blind,
placebo controlled studies in the target population. Another
20 studies were open label comparative trials and were ei-
ther dose-comparative or using an active comparator, his-
torical controls or standard care as controls. The majority
of studies were, however, uncontrolled or observational
“all-in-one” trials gathering as much data as possible in the
target paediatric population, including efficacy, safety, toler-
ability, activity and/or pharmacokinetics (Table 5).
To date, only one orphan medicinal product com-
pleted its PIP (Glivec®), all other PIPs are still on-going.
For four products the therapeutic indication has been
extended to the paediatric population [15,16]. On aver-
age, it takes seven years before PIPs are expected to be
completed.
Time course to marketing authorisation
Figure 2 illustrates the ODDs and MAs per year. The
Paediatric Drug Regulation did not significantly increase
the number of ODDs with potential paediatric indica-
tions (250/428 versus 420/660 of ODDs, χ2 = 2.78, p =
0.1) and did not lead to more MAs for ODs for children
(18/30 vs 22/51 of MAs, χ2 = 1.53, p = 0.22). Table 6
summarises the indication, age range and authorisation
details of MAs for use in the paediatric population.
The final model to analyse the time between ODD and
MA as survival time included after/before 2007 and age
group (child/ adult) as categorical variables. The resultsshow that after the implementation of the Paediatric
Drug Regulation in 2007, drug-indication-age combina-
tions, have a longer time to authorisation than before
January 2007 (Hazard ratio (95% CI) 2.804 (1.837-4.280),
p < 0.001, Figure 3A). The same effect was observed
when multiple indications of one drug were grouped
(data not shown). Potential paediatric use did not pro-
long the overall drug development process compared to
‘adults only’ medicinal products (Hazard ratio (95% CI)
1.140 (0.767-1.696), p = 0.52, Figure 3B).
The mean (95% CI) time to authorisation for paediat-
ric medicinal products after and before 2007 was 4.04
(3.02-5.07) and 2.93 (1.93-3.92). The mean (95% CI)
time to authorisation for adults-only products after and
before 2007 was 4.45 (3.78-5.12) and 2.07 (1.52-2.63)
years.
Repurposing does not provide any benefit in shorten-
ing the authorisation process for neither paediatric nor
adult ODs (p = 0.21, GLM, data not shown).
Discussion
More than 80 ODs, covering nearly 100 indications,
were authorised in Europe since 2000. Half of these
products are available for (a subgroup of) children. An-
other 34 authorised ODs are currently undergoing fur-
ther investigations in children. The introduction of the
Paediatric Drug Regulation was associated with a longer
time to MA for OD, did not significantly increase the
number of ODDs with potential paediatric indications
and did not lead to more MAs for paediatric indications.
In this study we were able to quantify the time to au-
thorisation and the number of paediatric ODs, but could
not extract the quality of research conducted in children
given the relatively young EU Paediatric Drug Regula-
tion. The use of Cox regression to analyse time to MA
as a survival function is appropriate and the data set is
large enough to draw valid conclusions. There is some
autocorrelation between indications for children and
adults within the same drug. This means that the time
to MA for a paediatric indication is linked to that for
adult indications of the same drug, because, in part, they
share study results. The data set illustrates that ODs
often obtain MA for adults first, for which clinical studies
are easier to conduct, and later for children. A control
group would have been desirable, but since non-ODs do
not have the same starting point (time of obtaining ODD),
comparison in this context is not possible and data would
have to be based on different criteria which is beyond the
scope of this study.
Administrative processes are not static, they change
over time, and that also applies to the approval of ODs.
This implies that the time to MA, modelled as survival
time in our Cox regression model, may not be com-
pletely independent of time. This time dependency was
Figure 2 New orphan drug designation and marketing authorisations
Table 5 Studies agreed upon in the PIPs of ODs
Measure N
Quality
- Development of age appropriate formulation 14
- Assessment of acceptability/ palatability 2
- Bioequivalence 1
- Microbiological testing 2
Total 19
Non-clinical





- Randomised, double blind, placebo controlled 25
- Comparative, open label 20
- Uncontrolled 41
- Observational 3
- Bioequivalence/ bioavailability 5
- (PB)PK 2
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gorical variable. Since the granted therapeutic indication
at the time of MA is the result of the assessment of the
quality, safety and efficacy data submitted with the mar-
keting application, this may be different (narrower) to
the indications proposed at the time of ODD application
[17]. After 2007, the Paediatric Committee (PDCO) safe-
guards that for any potential paediatric medicinal pro-
duct an investigation plan is made.
The situation for patients with rare diseases has, with-
out a doubt, improved dramatically after 2000, the year
in which the EU Orphan Drug Regulation was imple-
mented. Before 2000 only eight products, so called
orphan-like drugs, were authorised for the treatment of
rare diseases with the support of the EMA [18]. Four of
these orphan-like drugs were authorised for use in chil-
dren. In contrast, the United States introduced the Or-
phan Drug Act almost 20 years earlier, in 1983 [19].
Over the period 2000–2009, 148 (13%) of 1138 ODDs
received MA in the U.S., of which 81% were potentially
beneficial for children [20]. In the same period in the EU
only 55 of 703 of ODDs were authorised and only 52%
of the products were authorised in children.
The Paediatric Drug Regulation, implemented to in-
crease the availability of effective and safe drugs of good
quality for children, was also beneficial for ODs. The
majority of ODs with potential paediatric use that were
off label to children at the time of MA (40% of all ODs)
is currently in development for the paediatric popula-
tion. Also, 40% of ODs authorised for children are
undergoing further investigations to either expand the
intended treatment group to include younger childrenper year and age category.
Table 6 All ODs with MA for the paediatric population
Medicine name Active substance Indication Age range Authorisation date Status
Fabrazyme Agalsidase beta Fabry disease (galactosidase-A deficiency) 8 years and older 03/08/2001 End of marketing exclusivity
Replagal Agalsidase alpha Fabry disease (galactosidase-A deficiency) 7 years and older 03/08/2001 Authorised under exceptional
circumstance, end of
marketing exclusivity
Glivec Imatinib Chronic myeloid leukaemia > 1 and >2 years 07/11/2001 Withdrawn OD status
Tracleer Bosentan monohydrate Pulmonary arterial hypertension (PAH) 2 years and older 15/05/2002 Authorised
Zavesca Miglustat Niemann-Pick type-C disease Children* and adults 20/11/2002 Authorised
Carbaglu Carglumic acid Hyperammonaemia due to - N-acetylglutamate-synthase
(NAGS) primary deficiency





Aldurazyme Laronidase Mucopolysaccharidosis I (alpha-L-iduronidase deficiency) Children* and adults 10/06/2003 Authorised under exceptional
circumstance, end of
marketing exclusivity
Busilvex Busulfan Conditioning treatment prior to conventional
haematopoietic progenitor cell transplantation (HPCT)
Newborn and older 09/07/2003 End of marketing exclusivity
Lysodren Mitotane Advanced adrenal cortical carcinoma Children** and adults 28/04/2004 Authorised
Pedea Ibuprofen Patent ductus arteriosus Premature newborns 29/07/2004 Authorised
Wilzin Zinc Wilson’s disease One year and older 13/10/2004 Authorised
Xagrid Anagrelide Essential thrombocythaemia Children** and adults 16/11/2004 Authorised under exceptional
circumstances
Orfadin Nitisinone Hereditary tyrosinaemia type 1 (HT-1) Children* and adults 21/02/2005 Authorised
Revatio Sildenafil Pulmonary arterial hypertension one year and older 28/10/2005 Authorised
Naglazyme Galsulfase Mucopolysaccharidosis VI (N-acetylgalactosamine-4-sulfatase
deficiency; Maroteaux-Lamy syndrome)
Children* and adults 24/01/2006 Authorised under exceptional
circumstances
Myozyme Alglucosidase alpha Pompe disease (acid-α-glucosidase deficiency) Children of all ages and adults 29/03/2006 Authorised
Evoltra Clofarabine Acute lymphoblastic leukaemia 1-21 years 29/05/2006 Authorised under exceptional
circumstances
Exjade Deferasirox Beta thalassaemia major with iron overload 2 years and older 28/08/2006 Authorised
Diacomit Stiripentol Severe myoclonic epilepsy in infancy
(SMEI, Dravet's syndrome)
3 years and older 04/01/2007 Conditional approval





















Table 6 All ODs with MA for the paediatric population (Continued)
Inovelon Rufinamide Lennox-Gastaut syndrome 4 years and older 16/01/2007 Authorised
Cystadane Betaine anhydrous Homocystinuria Children* and adults 15/02/2007 Authorised
Soliris Eculizumab Paroxysmal nocturnal haemoglobinuria (PNH)
and atypical haemolytic uremic syndrome (aHUS)
Children* and adults 20/06/2007 Authorised
Siklos Hydroxycarbamide Sickle-cell syndrome 2 years and older 29/06/2007 Authorised
Increlex Mecasermin Primary insulin-like-growth-factor-1 deficiency
(primary IGFD)
2 to 18 years 03/08/2007 Authorised under exceptional
circumstances
Atriance Nelarabine Acute lymphoblastic leukaemia (T-ALL) and T-cell
lymphoblastic lymphoma (T-LBL)
Children* and adults 22/08/2007 Authorised under exceptional
circumstances
Kuvan Sapropterin dihydrochloride Phenylketonuria (PKU) and tetrahydrobiopterin
(BH4) deficiency
4 years and older 02/12/2008 Authorised
Mepact Mifamurtide Osteosarcoma 2 to 30 years 06/03/2009 Authorised
Peyona Caffeine citrate Primary apnoea Premature newborns 02/07/2009 Authorised
Mozobil Plerixafor Lymphoma and multiple myeloma Children** and adults 31/07/2009 Authorised
Cayston Aztreonam lysine Cystic fibrosis (CF) 6 years and older 21/09/2009 Authorised
Ilaris Canakinumab Cryopyrin-Associated Periodic Syndromes (CAPS),
and Systemic Juvenile Idiopathic Arthritis (SJIA)
2 years and older 23/10/2009 Authorised under exceptional
circumstances, withdrawn
OD status
Tepadina Thiotepa Allogeneic or autologous haematopoietic progenitor
cell transplantation (HPCT)
Children* and adults 15/03/2010 Authorised
Vpriv Velaglucerase alpha Type-1 Gaucher disease >2 years 26/08/2010 Authorised
Tobi Podhaler Tobramycin Cystic fibrosis 6 years and older 20/07/2011 Authorised
Votubia Everolimus Subependymal giant-cell astrocytoma (SEGA)
associated with tuberous-sclerosis complex (TSC)
3 years and older 02/09/2011 Conditional approval
Xaluprine 6-Mercaptopurine monohydrate Acute lymphoblastic leukaemia (ALL) Children* and adults 09/03/2012 Authorised
Kalydeco Ivacaftor Cystic fibrosis (CF) with G551D mutation in the
CFTR gene
6 years and older 23/07/2012 Authorised
Novothirteen Catridecacog Congenital factor-XIII-A-subunit deficiency 6 years and above 03/09/2012 Withdrawn OD status
Procysbi Mercaptamine bitartrate Nephropathic cystinosis Children* and adults 06/09/2013 Authorised
Orphacol Cholic acid Inborn errors in primary bile-acid synthesis
due to 3-hydroxy-5-C27-steroid oxidoreductase
deficiency or 4-3-oxosteroid-5-reductase deficiency
One month and older 12/09/2013 Authorised under exceptional
circumstances
Defitelio Defibrotide Severe hepatic veno-occlusive disease (VOD) in
haematopoietic stem-cell transplantation (HSCT) therapy
One month and older 18/10/2013 Authorised under exceptional
circumstances
*Age range not specified in SmPC.





















Figure 3 Cox regression survival curve as a function of (A) 2007 (after/ before) and (B) age group (child/ adult).
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youngsters. This would presumably not have taken place
without the instalment of the Paediatric Drug Regulation.
A drawback is the high number of deferrals for both
ordinary and orphan products. In deferrals, either initi-
ation or completion of paediatric studies is postponed
until the medicinal product is authorised for use in
adults, to ensure that it is safe to do research in chil-
dren and that availability for adults is not delayed.
In the 5 year progress report on the paediatric regula-
tion, the EMA concluded that authorisation of medi-
cines for adults was not delayed. However, in our
analysis, products authorised before 2007 had a shorter
time to MA than those authorised after the Paediatric
Drug Regulation came into force. Apparently the Paedi-
atric Drug Regulation added complexity to the R&D and
regulatory process of orphan medicinal products, exem-
plified by the applicants’ investments time and effort in
drafting a PIP.
Others also expressed concern that the EU Paediatric
Drug Regulation retards drug development and authorisa-
tion for adults by demanding paediatric trials, especially for
rare diseases [21,22]. It is not only the Paediatric Drug
Regulation that causes delay. There are potential other
product- and company-related factors such as the indica-
tion for which a drug is being developed, the type of drug
product in development, the company’s experience in de-
veloping OD and the size of the companies submitting the
MA application [23–25], and incentives such as those for
Small and Medium Sized companies implemented in De-
cember 2005 [26]. Other economic and bureaucratic issues
such as the increasing amount of regulations where appli-
cants have to comply with during drug development in
general have their effects. However, the increased approval
time after 2007 can also be an artefact, caused by the sub-
mission of ODD applications increasingly earlier in the de-
velopmental phase.
Given the relatively young EU Paediatric Drug Regula-
tion, there are few data on PIP completion and outcomein rare diseases, especially since deferrals lead to an add-
itional seven years before expected completion of the
files for paediatric indications. So far, only one product
successfully reached completion of development. Fur-
thermore, no orphan-designated medicine has yet ob-
tained the orphan incentive of two additional years of
market exclusivity. The impact of introducing PIPs will
become apparent in the next few years when more PIPs
are expected to be completed and will learn whether
applicants are compliant with measures and timelines
agreed upon in PIPs.
We could not demonstrate that repurposing is an ef-
fective strategy for the development of drugs for rare
diseases in children. Drug repurposing is considered an
interesting acceleration and facilitation of OD develop-
ment at lower cost and with lower risk of failure, since
these drugs have already been studied [7]. Although
repurposed drugs have already been studied in animals
and/or humans to some extent, a positive benefit/risk
balance has to be established for the intended paediatric
population. Since research in children on average takes
another seven years after safety and efficacy have been
confirmed in adults, this is considered to be the rate-
limiting step, irrespective of repurposing.
There is a need for novel research tools to support de-
cisions that balance between exposing children to exper-
iments and the obvious need to provide children with
authorised good quality drugs. Comparative trials are
considered the primary instrument to collect the evi-
dence needed for MA. However, for rare disease this is
often not feasible. In most cases, the studies requested
in the PIPs were open label uncontrolled studies. Most
studies were designed to collect as much data as pos-
sible, ranging from pharmacokinetics and dose finding
to safety and efficacy. When experimental research is
not feasible, on-going data collection through registry/
observational programs (such as named patient pro-
grammes (NPP) or compassionate use) are in place to
characterise both long-term safety and efficacy as well as
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sion [27,28]. There are differences in implementation of
legislation throughout the EU. For example, the French
authorities explicitly mention that investigation is not
the goal of an NPP and that an NPP may not replace a
clinical trial [29].
Several novel research strategies have been proposed,
such as meta-analytic approaches, extrapolation, modelling
and simulation. With the use of sparse sampling, popula-
tion pharmacokinetics/pharmacodynamics (POP-PK/PD)
and/or physiologically based pharmacokinetic models, ex-
trapolation from adults to children, interpolation between
paediatric age subgroups and the optimal use of scientific
literature and in vitro/preclinical data, drug development is
enriched while minimising the burden of studies in children
[30]. Since the implementation of the Paediatric Drug
Regulation, especially simulation and modelling are increas-
ingly used for paediatric drug development [15].
Non-clinical juvenile studies are often used to bridge
the knowledge gap between mature and immature sys-
tems, to detect safety issues early and to predict the dose
in children. A recent survey showed that in the majority
of juvenile toxicity studies, findings were comparable to
those for adults, yielding no new information [31]. Fur-
thermore, novel toxicity was uncommon and could have
been predicted from either known pharmacology or
from adult data. On the other hand, in a preliminary re-
view of 5 completed juvenile animal studies required in
PIPs, unexpected organ toxicity and increased sensitivity
was observed in 3 medicinal products, stressing the im-
portance of conduction juvenile animal studies [15]. It
confirms that drug development is not a “one size fits
all” process. A case-by-case evaluation process is neces-
sary, especially for paediatric ODs.
Part of paediatric drug development is to avoid dupli-
cation and to ensure that ongoing and planned paediat-
ric research is transparent. To this purpose, in March
2011, the EU Clinical Trials Register (EU-CTR) was
made publicly accessible (EU-CTR) for paediatric trials
included in a PIP [15]. The website (available at https://
www.clinicaltrialsregister.eu) provides public access to
information extracted from the EU clinical trials data-
base (EudraCT), such as protocols and known results.
The clinical trials included are those with agreed PIPs
from investigator sites within and outside the European
Economic Area (EEA). As soon as a paediatric trial is
approved, it becomes accessible in the database.
Conclusions
The EU Paediatric Drug Regulation did not increase the
number of ODDs with potential paediatric indications nor
did it lead to more MAs for paediatric indications. It was
associated with a longer time to MA for both adult and
paediatric orphan indications. Nonetheless, the PaediatricDrug Regulation has ensured the further paediatric deve-
lopment of drugs still off-label to children. The impact on
the quality and volume of research in the paediatric popu-
lation through PIPs will become clear in the coming few
years. Case-by-case assessment, based on innovative re-
search tools is necessary to collate the best evidence while
protecting children from unnecessary experiments.
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